DURHAM, N.C., May 14, 2025 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company, has announced the strategic prioritization and acceleration of its innovative PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD). This development targets dystrophin mutations within the common 'hot spot' region between exons 45-55. The company highlighted compelling preclinical evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, underscoring PBGENE-DMD's potential to durably improve muscle function. A conference call discussing this advancement is scheduled for May 15, 2025, at 8:00 AM ET, accessible via a live audio webcast on Precision BioSciences' investor site.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.